Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults who are 18 to 64 years of age (inclusive) at the time of first study vaccination.~* Written informed consent obtained from subject.~* Subjects who the investigator believes can and will comply with the requirements of the protocol .~* Healthy subjects as established by medical history and physical examination.~* Access to a consistent means of telephone contact.~* For subjects who undergo a screening visit: results of all safety laboratory tests obtained at the screening visit must be within reference ranges. Results of any repeat testing cannot be used to qualify a subject for enrolment.~* Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.~* Female subjects of childbearing potential may be enrolled in the study, if they~  * have practiced adequate contraception for 30 days prior to vaccination, and~ * have a negative pregnancy test on the day of vaccination, and~ * agree to continue to practice adequate contraception until 2 months after the last dose administered.~Exclusion Criteria:~* Presence or evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Presence or evidence of substance abuse.~* Diagnosed with cancer, or treatment for cancer within three years.~* Diagnosed with excessive daytime sleepiness, or narcolepsy; or history of narcolepsy in a subject's parent, sibling or child.~* Presence of a temperature ≥ 38.0ºC (≥100.4ºF), or acute symptoms greater than mild severity on the scheduled date of first vaccination.~* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.~* Receipt of systemic glucocorticoids within 30 days prior to the first dose of study vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs within 6 months of first study vaccine/ placebo dose.~* Any significant disorder of coagulation or treatment with warfarin derivatives or heparin.~* An acute evolving neurological disorder or Guillain Barré Syndrome within 42 days of receipt of prior seasonal or pandemic influenza vaccine.~* Administration of an inactive vaccine within 14 days or of a live attenuated vaccine within 30 days before the first dose of study vaccine/placebo.~* Planned administration of any vaccine other than the study vaccine/placebo before blood sampling at the Day 42 visit.~* Previous administration of any H7 vaccine or physician-confirmed H7 disease.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.~* Receipt of any immunoglobulins and/or any blood products within 90 days before the first dose of study vaccine/placebo, or planned administration of any of these products during the study period.~* Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine including a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.~* Known pregnancy or a positive urine beta-human chorionic gonadotropin (β-hCG) test result before the first dose of study vaccine/placebo.~* Lactating or nursing women.~* Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Formulation 1 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
- Formulation 2 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
- Formulation 3 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
- Formulation 4 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
- Formulation 5 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects in this group will receive two doses of placebo at a 21 day interval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete